Expert Consultations: Real-World Answers

Pharmacotherapy of Psychiatric Syndromes in Parkinson’s Disease – Interview

Published on April 1, 2020 Expired on April 1, 2023

Guest

Dana Wang

To unlock this audio you need to become a Silver, Gold, Silver extended or Gold extended Member.

Check Our CME Program

Downloads for Offline Access

Download Audio File (MP3)

Interview Highlights

Early cognitive impairment should make clinicians suspect atypical Parkinson’s syndromes.
Lewy body dementia and Parkinson’s disease dementia occur at different times in the clinical evolution of the disease, but the pathological findings at autopsies are very similar.
For sleep issues in Parkinson’s disease, start with sleep hygiene first; then evaluate if dopaminergic medications are taken too close to bedtime; and lastly, use sleep aids such as melatonin.

Text Version

This edition of Psychopharmacology Institute’s Expert Interviews features Gregory Pontone, M.D. Dr. Pontone is the Director of the Parkinson’s Disease Neuropsychiatry Clinic at Johns Hopkins University School of Medicine. In this interview, he will be discussing how to best manage psychiatric symptoms in Parkinson’s disease patients. This includes the interface between depression, anxiety, and Parkinson’s disease; atypical Parkinson’s

Unlock this Expert Consultation and earn 0.50 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.

Get Instant Access

Already have an account? Sign in

Learning Objectives:

After completing this activity, the learner will be able to:

Recognize the clinical differences between atypical Parkinson's syndromes and idiopathic Parkinson's disease.
Identify depression, anxiety, and sleep issues in Parkinson's disease patients to recommend the most adequate treatment.

Original Release Date: April 1, 2020

Review and Re-release Date: March 1, 2023

Expiration Date: April 1, 2023

Relevant Financial Disclosures:

Greg Pontone declares the following interests:

- Acadia Pharmaceuticals Inc: Consulting

All of the relevant financial relationships listed above have been mitigated by Medical Academy and the Psychopharmacology Institute.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

View the required educational content provided on this course page.
Answer the quiz for promoting retention of knowledge.
Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Gregory Pontone, M.D., M.H.S.